Licofelone - A novel analgesic and anti-inflammatory agent

Current Topics in Medicinal Chemistry

Volumn 7, Issue 3, 2007, Pages 251-263

  Kulkarni, S K ^a   Singh, Vijay Pal ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

5 LOX pathway; COX 2 inhibitors; Licofelone; NSAIDs induced gastrointestinal damage; PGH synthase

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ACETIC ACID; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BENOXAPROFEN; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ER 34122; INDOMETACIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; LIPID PEROXIDE; LIPOXYGENASE INHIBITOR; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TEBUFELONE; TEPOXALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON; ZUBRIN;

ABDOMINAL PAIN; ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; AREA UNDER THE CURVE; ASTHMA; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG INDUSTRY; DRUG MEGADOSE; DRUG RESEARCH; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERALGESIA; HYPERTENSION; INFLAMMATORY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MESENTERY DISEASE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PAW EDEMA; PERIPHERAL EDEMA; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; STOMACH DISEASE; STOMACH MUCOSA; STOMACH ULCER; STRUCTURE ANALYSIS; THROMBOSIS; WRITHING TEST;

ACETIC ACIDS; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CYCLOOXYGENASE INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS; PYRROLES;

EID: 33847657523     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941305     Document Type: Review

References (67)

1. Furst, D.E. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors. Am. J. Med. 1999, 107, 18S-26S.
2. Vane, J.R.; Blotting, R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rhematol. 1996, 25 (suppl 102), 9-21.
3. Warner, T.D.; Mitchell, J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB. J. 2004, 18, 790-804.
4. Chandrashekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tomsik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cycylooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Nalt. Acad. Sci. USA 2002, 99, 13926-13931.
5. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1520-1528.
6. US FDA (home page on internet). Center for Drug Evaluation and research. [Cited: 2004, Nov 18]. Available from http://www.fda.gov/cder.
7. Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoids biology. Science 2001, 294, 1875-1890.
8. Ding, C.; Cicuttini, F. Licofelone (Merckle). Drugs 2003, 6, 802-808.
9. Lewis, R.A.; Frank Austen, K.; Soberman, R.J. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 1990, 323, 645-655.
10. 4: A potential mediator of inflammation. J. Pharm. Pharmacol. 1980, 32, 517-518.
11. Bonnet. C.; Bertin, P.; Trèves, R.; Rigaud, M.; Lipoxygenase products and expression of 5LOX and FLAP in human synovial cells. Prostaglandins 1995, 50, 127-135.
12. Penrose, J.F.; Austen, K.F.; Lam, B.K. Leukotrienes: biosynthetic pathways, release and receptor mediated actions with relevance to diseases states. In Inflammation basic principles and clinical correlates; Gallin, J.L.; Snyderman, R Eds.; Lipincort Williams & Wilkins, Philadelphia, 1999; pp 361-372.
13. Rainsford, K.D. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal damage. Agents Actions 1993, 39, C24.-C26.
14. 4 in mucosal damage caused by necrotizing agents, and indomethacin, in rat stomach. Gastroenterology, 1991, 100, 619-626.
15. Rainsford, K.D. Mechanism of arachidonic acid ulceration from non-steroidal anti-inflammatory drugs: A basis for use and development of protective agents. In: Side effects of anti-inflammatory drugs, Rainsfrord, K.D.; Velo, G.P.; Eds; Kluwer Academic Publishers: Lancaster. 1992; pp 97-114.
16. Shishido, Y.; Furushiro, M.; Hashimoto, S.; Yokokura, T. Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia. Pharmacol. Biochem. Behav. 2001, 69, 469-474.
17. O'Donnell, J.L.; O'Donnell, A.L. Prostaglandin E2 content in herniated lumbar disc disease. Spine 1996, 21, 1653-1656.
18. Nygaard, O.P.; Mellgren, S.I.; Osterud, B. The inflammatory properties of contained and non-contained lumbar disc herination. Spine 1997, 22, 2484-2488.
19. 4 in radicular pain induced by herniated nucleus pulposus. J. Orthop. Res. 2001, 19, 472-477.
20. Sharon, P.; Stenson, W.F. Enhanced synthesis of leukotrienes by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86, 453-460.
21. Zouboulis, C.C.; Nestoris, S.; Adler, Y.D.; Orth, M.; Orfanos, C.E.; Picardo, M. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch. Dermatol. 2003, 139, 668-670.
22. Knapp, H.R. Reduced allergen induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med. 1990, 323, 1745-1748.
23. Weinblatt, M.E.; Kremer, J.M.; Coblyn, J.S.; Helfgott, S.; Maier, A.L.; Petrillo, G. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J. Rhematol. 1992, 19, 1537-1541.
24. Collawn, C.; Rubin, P.; Perez, N.; Bobadilla, J.; Cabrera, G.; Reyes, E.; Borovoy, J.; Kershenobich, D. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am. J. Gastroenterol. 1992, 87, 342-346.
25. Singh, V. P.; Patil, C. S.; Kulkarni, S.K. Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats. Indian J. Exp. Biol. 2004, 42, 667-673.
26. Hawkey, C.J.; Rampton, D.S.; Benoxaprofen in the treatment of active ulcerative colitis. Prostaglandins Leukot. Med. 1983, 10, 405-409.
27. Singh, V. P.; Patil, C. S.; Kulkarni, S.K. Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats. Inflammopharmacology 2004, 12, 189-95.
28. Singh, V. P.; Patil, C. S.; Kulkarni, S.K. Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats. Pharmacol. Biochem. Behav. 2005, 81, 433-439.
29. Nickerson-Nutter, C.L.; Medvedeff, E, D. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996, 39, 515-521.
30. Pelletier, J. M.; Lajeunesse, D.; Reboul, P.; Pelletier, J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003, 62, 501-509.
31. Wallace, J.L.; McKnight, G.W.; Keenan, C.M.; Byles, N.I.; MacNaughton, W.K. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 1990, 98, 1178-1186.
32. Gaetano, G. de.; Donati, M. D.; Cerletti, C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. TIPS, 2003, 24, 245-251.
33. Leval, X.; Julemont, F.; Delarge, J.; Pirotte, B.; Dogue, J.M. New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem. 2002, 9, 941-962.
34. Higgs, G.A.; Mugridge, K.G.; Moncada, S.; Vane, J.R. Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C. Proc. Nalt. Acad. Sci. USA. 1984, 81, 2890-2892.
35. Horizoe, T.; Nagakura, N.; Chiba, K.; Shirota, H.; Shinoda, M.; Numata, H.; Kobayashi, S.; Abe, C. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice. Inflamm. Res. 1999, 48, 432-436.
36. Horizoe, T.; Nagakura, N.; Chiba, K.; Shirota, H.; Shinoda, M.; Kobayashi, N.; Numata, H.; Okamoto, Y.; Kobayashi, S. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm. Res. 1998, 47, 375-383.
37. Knight, E.V.; Kimball, J.P.; Keenan, C.M.; Smith, I.L.; Wong, F.A.; Barrett, D.S.; Dempster, A.M.; Lieuallen, W.G.; Panigrahi, D.; Powers, W.J.; Szot, R.J. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam. Appl. Toxicol. 1996, 33, 38-48.
38. Kirchner, T.; Aparicio, B.; Argentieri, D.C.; Lau, C.Y.; Ritchie, D.M. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot. Essent. Fatty. Acids. 1997, 56, 417-423.
39. Waldman, S.A.; Vitow, C.; Osborne, B.; Gillen, L.; Argentieri, D.C.; Wong, F.A.; Smith, I.L.; Chow, A.T.; Misiti, J.; Bjornsson, T.D. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. J. Clin. Pharmacol. 1996, 36, 462-468.
40. Wong, S.; Lee, S.J.; Frierson, M.R. 3rd.; Proch. J.; Miskowski, T.A.; Rigby, B.S.; Schmolka, S.J.; Naismith, R.W.; Kreutzer, D.C.; Lindquist, R. Antiarthritic profile of BF-389-a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992, 37, 90-98.
41. Laufer, S.A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem. 1994, 37, 1894-1897.
42. Rotondo, S.; Dell'Elba, G.; Krauze-Brzosko, K.; Manarini, S.; Martelli, N.; Pecce, R.; Evangelista, V.; Cerletti, C. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function. Eur. J. Pharmacol. 2002, 18, 131-139.
43. Algate, D.R.; Augustin, J.; Atterson, P.R.; Beard, D.J.; Jobling, C.M.; Laufer, S.; Mont, P.L.; Tries, S. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-pheny1-2,3-dihydro-1H-pyrrolizine- 5-yl]-acetic acid in experimental animals. Arzneimittelforschung 1995, 45, 159-165.
44. Singh, V. P.; Patil, C. S.; Kulkami, S.K. Antiinflammatory effect of licofelone against various inflammatory challenges. Fundam. Clin. Pharmacol. 2006, 20, 65-71.
45. Tries. S.; Laufer, S. The pharmacological profile of ML 3000: A new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase. Inflammopharmacology 2001, 9, 113-124.
46. Singh, V. P.; Patil, C. S.; Kulkarni, S.K. Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain. Pharmacol. Rep. 2005, 57, 380-384.
47. Abraham, W.M.; Tries. S.; Laufer, S. The effects of ML 3000 on antigen-induced responses in sheep. Pulm. Pharmacol. Ther. 1997, 10, 167-173.
48. Tries, S.; Laufer, S.; Radziwon, P.; Breddin, H.K. Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with COX/5-LOX inhibitory activity. Inflamm. Res. 2002, 51, 129-134.
49. Jovanovic, D.V.; Fernandes, J.C.; Martel-Pelletier, J.; Jolicoeur, F.C.; Reboul, P.; Laufer, S.; Tries, S.; Pelletier, J.P. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum. 2001, 44, 2320-2330.
50. Lajeunesse, D.; Pelletier, J.M.; Fernandes, J.C.; Laufe, S.; Pelletier, J.P. Treatment with licofelone prevents abnormal subchondreal bone cell metabolism in experimental dog arthritis. Ann. Rheum. Dis. 2004, 63, 73-83.
51. 14C]labeled [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine- 5-yl]-acetic acid in rats. Arzneimittelforschung 1995, 45, 272-276.
52. Heidemann, A.; Tries, S.; Laufer, S.; Augustin, J. Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine- 5-yl]-acetic acid. Arzneimittelforschung 1995, 45, 486-490.
53. Wallace, J.L.; Carter, L.; McKnight, W.; Tries, S.; Laufer, S. ML3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur. J. Pharmacol. 1994, 271, 525-531.
54. Laufer, S.; Tries, S.; Augustin, J.; Elsasser, R.; Algate, P.R.; Munt, P.L. Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine- 5-yl]-acetic acid in rat. Arzneimittelforschung 1994, 44, 1329-1333.
55. Tries, S.; Neupert, W.; Laufer, S. The mechanism of action of the new anti-inflammatory compound ML3000 Inhibition of 5-LOX and COX-1/2. Inflamm. Res. 2002, 51, 135-143.
56. Singh, V. P.; Patil, C. S.; Kulkarni, S.K. Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Ind. J. Exp. Biol. 2005, 43, 247-253.
57. Smolka, A.J.; Goldenring, J.R.; Gupta, S.; Hammond, C.E. Inhibition of gastric H,K ATPase activity and gastric epithelial cell IL-8 secretion by pyrrolizine derivative ML3000, BMC Gastroenterol. 2004, 10, 4-10.
58. Fiorucci, S.; Distrutti, E.; de Lima, O. M.; Romano, M.; Mencarelli, A.; Barbanti, M.; Palazzini, E.; Morelli, A.; Wallace, J.L. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J. 2003, 17, 1171-1173.
59. Albrecht, W.; Bias, P.; Lammerich, A.; Carre, C.; Clerch, L. Pharmacokinetics, safety, and tolerability of licofelone (ML3000) 200 mg bid given with food in young and elderly healthy volunteers. Ann. Eur. Congr. Rheumatol. 2002, 12-15, AB0293.
60. Albrecht, W.; Bias, P.; Lammerich, A. Investigation of the single-dose pharmacokinetics of warfarin during repeated administration of licofelone (ML 3000) 200 mg bid to healthy volunteers Ann. Eur. Congr. Rheumatol. 2002, 12-15, AB0295.
61. ML 3000, the parent drug of new category of anti-inflammatory agents, double acting anti-inflammatory drugs (DAAD), shows outstanding gastroduodenal tolerability in clinical studies. Alfa Wassermann SpA. Press Release 1999, June 16.
62. Forest laboratories announces positive results with ML 3000 in early clinical trials. Forest laboratories Inc. Press Release 2000, March 29.
63. Positive ML 3000 clinical trial results announced by EuroAlliance at OARSI meeting in Barcelona. Alfa Wassermann SpA Press Release 2000, October.
64. Reginster, J., Bias. P.; Buchner, A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2, and 5-LOX, for the treatment of osteoarthritis. Ann. Rheum. Dis. 2002, 61 (suppl), 116.
65. Blanco, F.J.; Buchner. A., Bias, P. Licofelone, an inhibitor of COX-1, COX-2, and 5-LOX, is as effective as naproxen and shows improved safety during 12 weeks treatment in patients with osteoarthritis of the knee. Ann. Rheum. Dis. 2003, 62(suppl), 261.
66. Skelly, M.M.; Hawkey, C.J. Potential alternatives to COX-2 inhibitors. New molecules may overtake the COX-2 inhibitors debate. Br. Med. J. 2002, 324, 1289-1290.
67. Langman, M.J.S. Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundam. Clin. Pharmacol. 2003, 17, 393-403.